Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trialJane C. Burns, Nichole Samuy, Samantha C. Roberts et al.|The Lancet Child & Adolescent Health|2021Cited by 113
Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery AneurysmAdriana H. Tremoulet, Jane C. Burns, Sonia Jain et al.|The Journal of Pediatrics|2019Cited by 39
Circulating microRNAs differentiate Kawasaki Disease from infectious febrile illnesses in childhoodPei‐Ni Jone, Shelley D. Miyamoto, Armin Korst et al.|Journal of Molecular and Cellular Cardiology|2020Cited by 38
Procalcitonin (PCT) and Kawasaki Disease: Does PCT Correlate With IVIG-Resistant Disease, Admission to the Intensive Care Unit, or Development of Coronary Artery Lesions?Samuel R. Dominguez, Mary P. Glodé, Blake Martin et al.|Journal of the Pediatric Infectious Diseases Society|2015Cited by 37
Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery LesionsPei‐Ni Jone, Samuel R. Dominguez, Marsha S. Anderson et al.|The Pediatric Infectious Disease Journal|2018Cited by 36